Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Medicine, Pathology, Mesothelioma, Lung, Pathological, and Lung cancer.
CHIMERA: a phase II study of neoadjuvant pembrolizumab in combination with cisplatin or carboplatin and pemetrexed followed by surgery and adjuvant pembrolizumab in resectable pleural mesothelioma
Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma
Detection of lung allograft injury through a comprehensive multidisciplinary analysis of donor-derived cell-free DNA in plasma and bronchoalveolar lavage: a real-world single center experience
248TiP: Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemoimmunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA study)
Tertiary lymphoid structures and B-cell infiltration are IPF features with functional consequences
The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?
Comprehensive bronchoalveolar lavage characterization in COVID-19 associated acute respiratory distress syndrome patients: a prospective cohort study
Assessing the role of phosphorylated S6 ribosomal protein in the pathological diagnosis of pulmonary antibody-mediated rejection
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
Machine learning‐based analysis of alveolar and vascular injury in <scp>SARS‐CoV</scp>‐2 acute respiratory failure
Proven COVID‐19—associated pulmonary aspergillosis in patients with severe respiratory failure
COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City
Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists
Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study
Are There New Biomarkers in Tissue and Liquid Biopsies for the Early Detection of Non-Small Cell Lung Cancer?
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor heterogeneity over time
Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal